JHEP|Reports

Journal of Hepatology

CTAT methods

Tables for a "Complete, Transparent, Accurate and Timely account" (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as 'Supplementary CTAT Table'
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

1.1   Antibodies

Name	Supplier	Cat no.
SARS-COV-2 S Protein RBD Mouse IgG2a Fc Tag	AcroBiosystems	SPD-C5259
SARS-COV-2 S (COVID-19) S1 Protein, His Tag	AcroBiosystems	S1N-C52H4
Biotinylated Human ACE2 His, Avitag	AcroBiosystems	AC2-H82E6
SARS-CoV-2 Spike (L452R, T478K)Delta RBD Protein (His Tag)	Sino Biologicals	40592-V08H90
SARS-CoV-2B1.1.529 (Omicron) Spike RBD Protein (His Tag)	Sino Biologicals	40592-V08H121
SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (His tag)	Sino Biologicals	40588-V07E
goat anti-human IgG Fc horseradish peroxidase (HRP) conjugated	Invitrogen	A24476
goat anti-human IgM µ chain HRP conjugated	Abcam	ab97205

1.2   Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method

1.3   Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number

1.4   Sequence based reagents

Name	Sequence	Supplier

1.5   Biological samples

Description	Source	Identifier

1.6   Deposited data

Name of repository	Identifier	Link

1.7   Software

Software name	Manufacturer	Version

1.8   Other (e.g. drugs, proteins, vectors etc.)

Moderna/NIAID mRNA-1273 mRNA vaccine	BioNTech-Pfizer BNT162b2 mRNA vaccine	AstraZeneca/University of Oxford ChAdOx1 adenoviral vectored vaccine

1.9   Please provide the details of the corresponding methods author for the manuscript:

Rui Eduardo Castro, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal. Phone: +351 21 794 6400; Fax: +351 21 794 6491; email: ruieduardocastro@ff.ulisboa.pt

2.0   Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.